medi.ru Ìóêîâèñöèäîç (MB) ). Åñòü ñîîáùåíèÿ (1996 ã.) î 30-ëåòíåé ïðîäîëæèòåëüíîñòè æèçíè (CCF patient registry 1996; Annual Data Report). Ïðîöåíò âçðîñëûõ áîëüíûõ âûðîñ ñ 22,8% â 1977 ãîäó äî 31,3% â 1989 ãîäó 2. Tsui, L.-C. and Durie, P. Genotype and phenotype in cystic fibrosis. Hospital Practice 115-142 (1997) 3. Rosenstein, Â. J. and Zeitlin, P. L. Cystic fibrosis. The Lancet 351: 277-282 (1998) 4. Leonard, Ñ. Í. and Knox. A. J. Pancreatic enzyme supplements and vitamins in cystic fibrosis. J Hum Nutr Dietet 10: 3-16 (1997) 5. Aitken, M. L. and Fiel, S. B. Cystic fibrosis. Disease-a-Month 6-52 (1993) 6. George, D. E. et al. Comparison of two pancreatic enzyme supplements in patients with cystic fibrosis. Adv Ther 7(3): 109-118 (1990) 7. De Boeck, Ê. et al. Lipid digestion in cystic fibrosis: Comparison of conventional and high lipase enzyme therapy using the mixedtriglyceride breath test. J Red Gastroenterol Nut 26: 408-411 (1998) 8. Robinson, P. J. and Natoli, G. Comparison of high-dose and standarddose pancreatic enzyme capsules in children with cystic fibrosis. Aust J Hosp Pharm 28: 160-164 (1998) 9. Braden, Â. et al. Monitoring pancreatin supplementation in cystic fibrosis patients with the 13C-Hiolein breath test: evidence of normalized fat assimilation with high dose pancreatin therapy. Z Gastroenterol 35: 123-129 (1997) | |
|